Login / Signup

Studies on spiro[4.5]decanone prolyl hydroxylase domain inhibitors.

James P Holt-MartynAnthony TumberMohammed Z RahmanKerstin LipplWilliam D FiggMichael A McDonoughRasheduzzaman ChowdhuryChristopher J Schofield
Published in: MedChemComm (2019)
The 2-oxoglutarate (2OG) dependent hypoxia inducible factor (HIF) prolyl hydroxylases (PHDs) are targets for treatment of anaemia and other ischaemia related diseases. PHD inhibitors are in clinical trials; however, the number of reported templates for PHD inhibition is limited. We report structure-activity relationship and crystallographic studies on spiro[4.5]decanone containing PHD inhibitors. Together with other studies, our results reveal spiro[4.5]decanones as useful templates for generation of potent and selective 2OG oxygenase inhibitors.
Keyphrases
  • clinical trial
  • case control
  • structure activity relationship
  • randomized controlled trial
  • gene expression
  • endothelial cells
  • combination therapy
  • smoking cessation
  • study protocol
  • double blind